Recent advances have seen immuno-therapy become a shining light within oncology research, transforming both the way cancer treatments are viewed and the potential standards of care and outcomes.
The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
